{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T15:39:19Z","timestamp":1785425959640,"version":"3.56.0"},"reference-count":16,"publisher":"American Association for Cancer Research (AACR)","issue":"7","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P50CA186781"],"award-info":[{"award-number":["P50CA186781"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Naturally occurring tumor-specific T cells derived from peripheral blood (PB) offer a clinically accessible source for adoptive immunotherapy. However, the expansion of these T cells from patients with cancer remains a challenge. We hypothesized that mimicking innate immune activation could optimally stimulate antigen-driven T-cell expansion in vitro, unlocking the therapeutic potential of PB-derived T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>We previously developed an ex vivo culture system that selectively expands tumor antigen\u2013activated T cells from PB mononuclear cells (PBMC), generating multiclonal effector and central memory T cells. In this hypothesis-generating study, we evaluated the therapeutic potential of MUC1-activated T cells in patients with relapsed and\/or refractory multiple myeloma (r\/rMM) in a phase I clinical trial (NCT05411497). MUC1 is an oncoprotein overexpressed in r\/rMM. We translated our small-scale culture into GMP-compliant, large-scale manufacturing, which achieved expansion of T cells from heavily pretreated patients\u2019 PBMCs without exhaustion. Five patients were treated with escalating doses of up to 1 \u00d7 1010 T cells.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Although the cell infusions were well tolerated, no objective responses occurred. One patient, who received the highest dose, has had stable disease for 2 years after infusion. This patient exhibited transient dermatitis with localized MUC1 and CD3 staining, as potential evidence of on-target, off-tumor T-cell reactivity, perhaps contributing to disease stabilization. T-cell receptor sequencing revealed the T-cell product in four of the patients\u2019 blood, which correlated with the product\u2019s degree of polyfunctionality and MUC1 reactivity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These findings demonstrate the feasibility, safety, and biological activity of PB-derived, MUC1-specific T cells as adoptive immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>Expanding tumor antigen\u2013specific T cells for clinical use from the blood of heavily pretreated patients with cancer remains a significant hurdle. We scale up a novel culture method that integrates innate immune signals to stimulate T-cell expansion and demonstrate safety, feasibility, and a case of long-term disease stabilization upon treatment of patients with multiple myeloma in a phase I clinical trial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-25-0713","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T15:12:06Z","timestamp":1781190726000},"page":"1592-1604","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Evaluation of\n                    <i>Ex Vivo<\/i>\n                    Expanded MUC1-Specific Peripheral Blood T Cells for Adoptive Immunotherapy in Relapsed\/Refractory Multiple Myeloma"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9709-7624","authenticated-orcid":false,"given":"Erin W.","family":"Meermeier","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 1 Department of Immunology, , Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8094-5626","authenticated-orcid":false,"given":"Dara S.","family":"Missan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 2 Center for Regenerative Biotherapeutics, , Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2213-0910","authenticated-orcid":false,"given":"Latha B.","family":"Pathangey","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 1 Department of Immunology, , Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9561-140X","authenticated-orcid":false,"given":"Caleb K.","family":"Stein","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 3 Division of Hematology and Oncology, , Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3939-230X","authenticated-orcid":false,"given":"Gabrielle A.","family":"Reckard","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 2 Center for Regenerative Biotherapeutics, , Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-3438-4419","authenticated-orcid":false,"given":"Susie A.","family":"Darvish","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 3 Division of Hematology and Oncology, , Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1841-6017","authenticated-orcid":false,"given":"Gregory J.","family":"Ahmann","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 3 Division of Hematology and Oncology, , Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8862-4808","authenticated-orcid":false,"given":"Jill","family":"Adamski","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 4 Department of Laboratory Medicine and Pathology, , Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5938-3769","authenticated-orcid":false,"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 3 Division of Hematology and Oncology, , Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0365-933X","authenticated-orcid":false,"given":"Sandra J.","family":"Gendler","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 1 Department of Immunology, , Scottsdale, Arizona."},{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 5 Department of Biochemistry and Molecular Biology, , Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5514-7072","authenticated-orcid":false,"given":"Michael P.","family":"Gustafson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 1 Department of Immunology, , Scottsdale, Arizona."},{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 2 Center for Regenerative Biotherapeutics, , Phoenix, Arizona."},{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 4 Department of Laboratory Medicine and Pathology, , Phoenix, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1523-7388","authenticated-orcid":false,"given":"P. Leif","family":"Bergsagel","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qp3tb03","id-type":"ROR","asserted-by":"publisher"}],"name":"Mayo Clinic 3 Division of Hematology and Oncology, , Scottsdale, Arizona."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"2026070714345523000_bib1","doi-asserted-by":"crossref","first-page":"e010687","DOI":"10.1136\/jitc-2024-010687","article-title":"Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed\/refractory multiple myeloma","volume":"13","author":"Jin","year":"2025","journal-title":"J Immunother Cancer"},{"key":"2026070714345523000_bib2","doi-asserted-by":"crossref","first-page":"10785","DOI":"10.18632\/oncotarget.13911","article-title":"Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2\/neu and other tumor-associated antigens","volume":"8","author":"Pathangey","year":"2017","journal-title":"Oncotarget"},{"key":"2026070714345523000_bib3","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.18632\/oncotarget.28067","article-title":"Multipeptide stimulated PBMCs generate T(EM)\/T(CM) for adoptive cell therapy in multiple myeloma","volume":"12","author":"Vardam-Kaur","year":"2021","journal-title":"Oncotarget"},{"key":"2026070714345523000_bib4","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1007\/s12185-023-03579-x","article-title":"Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy","volume":"117","author":"Russell","year":"2023","journal-title":"Int J Hematol"},{"key":"2026070714345523000_bib5","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1146\/annurev.physiol.70.113006.100659","article-title":"Structure and function of the cell surface (tethered) mucins","volume":"70","author":"Hattrup","year":"2008","journal-title":"Annu Rev Physiol"},{"key":"2026070714345523000_bib6","doi-asserted-by":"crossref","first-page":"4475","DOI":"10.1007\/s00018-015-2014-z","article-title":"MUC1 (CD227): a multi-tasked molecule","volume":"72","author":"Apostolopoulos","year":"2015","journal-title":"Cell Mol Life Sci"},{"key":"2026070714345523000_bib7","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1124\/mol.110.065011","article-title":"Survival of human multiple myeloma cells is dependent on MUC1 C-terminal transmembrane subunit oncoprotein function","volume":"78","author":"Yin","year":"2010","journal-title":"Mol Pharmacol"},{"key":"2026070714345523000_bib8","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1182\/blood-2015-07-659151","article-title":"MUC1-C drives MYC in multiple myeloma","volume":"127","author":"Tagde","year":"2016","journal-title":"Blood"},{"key":"2026070714345523000_bib9","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/bjh.13245","article-title":"Phase I\/II study exploring ImMucin, a pan-major histocompatibility complex, anti-MUC1 signal peptide vaccine, in multiple myeloma patients","volume":"169","author":"Carmon","year":"2015","journal-title":"Br J Haematol"},{"key":"2026070714345523000_bib10","doi-asserted-by":"crossref","first-page":"38974","DOI":"10.18632\/oncotarget.9777","article-title":"MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia","volume":"7","author":"Tagde","year":"2016","journal-title":"Oncotarget"},{"key":"2026070714345523000_bib11","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","article-title":"Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes","volume":"56","author":"Skerget","year":"2024","journal-title":"Nat Genet"},{"key":"2026070714345523000_bib12","doi-asserted-by":"crossref","first-page":"e0121546","DOI":"10.1371\/journal.pone.0121546","article-title":"A method for identification and analysis of non-overlapping myeloid immunophenotypes in humans","volume":"10","author":"Gustafson","year":"2015","journal-title":"PLoS One"},{"key":"2026070714345523000_bib13","doi-asserted-by":"crossref","first-page":"640725","DOI":"10.3389\/fimmu.2021.640725","article-title":"TCRMatch: predicting T-cell receptor specificity based on sequence similarity to previously characterized receptors","volume":"12","author":"Chronister","year":"2021","journal-title":"Front Immunol"},{"key":"2026070714345523000_bib14","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","article-title":"Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma","volume":"106","author":"Bergsagel","year":"2005","journal-title":"Blood"},{"key":"2026070714345523000_bib15","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/978-1-4939-9773-2_19","article-title":"Single-cell multiplexed proteomics on the IsoLight resolves cellular functional heterogeneity to reveal clinical responses of cancer patients to immunotherapies","volume":"2055","author":"Liu","year":"2020","journal-title":"Methods Mol Biol"},{"key":"2026070714345523000_bib16","doi-asserted-by":"crossref","first-page":"eaaz3339","DOI":"10.1126\/scitranslmed.aaz3339","article-title":"The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma","volume":"12","author":"Lulla","year":"2020","journal-title":"Sci Transl Med"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-25-0713\/3803297\/crc-25-0713.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1592\/3810186\/crc-25-0713.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/7\/1592\/3810186\/crc-25-0713.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:35:09Z","timestamp":1783449309000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/7\/1592\/786392\/Clinical-Evaluation-of-Ex-Vivo-Expanded-MUC1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":16,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-25-0713","relation":{},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}